A WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation
The Lancet Microbe · 2026-11 · 7 (11) · 101465
DOI: 10.1016/j.lanmic.2026.101465 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Microbe, 2026-11. Verfasst von Sally A Baylis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Paul-Ehrlich-Institut, Langen, Germany. Electronic address: Sally.Baylis@pei.de. Hauptthemen laut MEDLINE: Chikungunya virus, Antibodies, Viral, Chikungunya Fever, Antibodies, Neutralizing. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Ministry of Health.
Abstract (Originalsprache)
Background
Chikungunya fever is a mosquito-borne disease characterised by severe arthralgia and is caused by chikungunya virus (CHIKV), an alphavirus. The aim of this study was to establish a WHO International Standard for CHIKV-specific neutralising antibodies–a potential correlate of protection.
Methods
Two candidate International Standards (code numbers 1502/19 and 1504/19) were prepared: 1502/19 using plasma from a CHIKV-convalescent individual and 1504/19 using plasma from blood donors from a CHIKV-endemic region. Potencies of the two candidate International Standards were evaluated alongside samples from recovered individuals and donors previously infected with CHIKV, in an international study (2019–20), using a range of virus-neutralisation assays and immunoassays. Statistical analysis was used to estimate mean and relative potencies of the candidate International Standards. Participants included vaccine developers, arbovirus reference laboratories, and diagnostics manufacturers.
Findings
26 laboratories from 12 countries reported detection of anti-CHIKV antibodies and associated potencies. All participants consistently detected both 1502/19 and 1504/19. Overall mean potencies were near-identical for the two candidate International Standards (1502/19, 3·44 log 10 and 1504/19, 3·48 log 10 ). Intra-assay variation was considerably lower than inter-assay variation for the candidate International Standards, which varied by more than 100-fold; this variability was seen for all other anti-CHIKV-positive samples. Assay variability was substantially reduced when antibody titres from the panel of samples were expressed relative to 1502/19 or 1504/19. An agreement was reached to establish 1502/19 as the first WHO International Standard for anti-CHIKV neutralising antibodies, with an assigned unitage of 1000 International Unitage/mL.
Interpretation
The use of the candidate International Standards resulted in harmonisation of anti-CHIKV neutralisation titres, allowing for better comparison of results of neutralisation assays for anti-CHIKV antibodies, either as a consequence of natural infection or produced in response to different vaccines, and will be essential in estimating antibody titres associated with protection against CHIKV. Funding: German Ministry of Health (Bundesministerium für Gesundheit).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Paul-Ehrlich-Institut, Langen, Germany. Electronic address: Sally.Baylis@pei.de.
- Paul-Ehrlich-Institut, Langen, Germany.
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Institute for Transfusion Medicine and Gene Therapy, Medical Center, University of Freiburg, Freiburg, Germany.
- Instituto Oswaldo Cruz, Fundaçăo Oswaldo Cruz, Rio de Janeiro, Brazil.
- School of Health, University of the Sunshine Coast, Petrie, QLD, Australia; Australian Red Cross Lifeblood, Brisbane, QLD, Australia.
Förderung
- German Federal Ministry of Health
Zitieren
APA
Baylis, S. A., Yue, C., Panning, M., Pauly, M. C., Lewis-Ximenez, L. L., Faddy, H. M., Simmons, G., Busch, M., Schnierle, B. S., Roth, H., Hanschmann, K. O., & Collaborative Study Group (2026). A WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation. The Lancet Microbe, 7(11), 101465. https://doi.org/10.1016/j.lanmic.2026.101465
Vancouver
Baylis SA, Yue C, Panning M, Pauly MC, Lewis-Ximenez LL, Faddy HM, et al. A WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation. The Lancet Microbe. 2026;7(11):101465. doi:10.1016/j.lanmic.2026.101465
BibTeX
@article{Baylis2026,
author = {Baylis, Sally A and Yue, Constanze and Panning, Marcus and Pauly, Marie-Christin and Lewis-Ximenez, Lia Laura and Faddy, Helen M and Simmons, Graham and Busch, Michael and Schnierle, Barbara S and Roth, Hanna and Hanschmann, Kay-Martin O and Collaborative Study Group, Collaborative Study Group},
title = {A WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation},
journal = {The Lancet Microbe},
year = {2026},
volume = {7},
number = {11},
pages = {101465},
doi = {10.1016/j.lanmic.2026.101465}
}
EUVIMED